Reply by tumor induced Gemcitabine progressive and constant in a patient with uterine Leiomyosarcoma Searing resistant

T. Pas de, g. Spitaleri, p. Della Vigna, f. Curigliano Toffalorio, g., r. Gambino, s. Boselli, f. de Braud

Background: Despite the combination of Gemcitabine (GCB) and docetaxel showed a benefit on the disease-free survival and overall survival than only GCB in patients with soft tissue sarcoma, GCB mono-chemotherapy should be a preferable option than the combination, because of its low toxicity profile and its ability to be administered permanently for a long date.

Causal relationship: We report a case report of a woman with advanced high degree uterine Leiomyosarcoma refractory to ifosfamide, doxorubicin and trabectedin, who have experienced a sustained response and progressive GCB alone.

Conclusions: Gemcitabine even when given as a mono-chemotherapy can achieve a lasting control of cancer in patients with pre-treated LMS heavy uterine and should be considered as a possible option for this subgroup of patients.

Volume: 2 article number: 102 DOI: 10.3332/ecancer. 2008 102 received: 22/10/2008 published: 24/11/2008

To view this article in its entirety, you must first sign in or register.

View the original article here